

1 Evaluating the causal association between type 2 diabetes and Alzheimer’s disease: a Two-  
2 Sample Mendelian Randomization Study

3

4 Si Han<sup>1</sup>, Tom Lelieveldt<sup>2</sup>, Miriam Sturkenboom<sup>1</sup>, Geert Jan Biessels<sup>3</sup>, Fariba Ahmadizar<sup>1,4\*</sup>

5

6 <sup>1</sup>Department of Data Science and Biostatistics, Julius Global Health, University Medical

7 Center Utrecht, Utrecht, The Netherlands

8 <sup>2</sup>Department of Biomedical Science, University College Utrecht, Utrecht University, The

9 Netherlands

10 <sup>3</sup>Department of Neurology, Brain Center, University Medical Center Utrecht, Utrecht, The

11 Netherlands

12 <sup>4</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA

13

14

15 \*Corresponding author:

16 Fariba Ahmadizar, PharmD, PhD

17 Email: [f.ahmadizar@umcutrecht.nl](mailto:f.ahmadizar@umcutrecht.nl)

18

## 19 **Abstract**

20

## 21 **Aims**

22 Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are significant global health  
23 issues. Epidemiological studies suggest T2DM increases AD risk, though confounding  
24 factors and reverse causality complicate this association. This study aims to clarify the causal  
25 relationship between T2DM and AD through a systematic review and meta-analysis of  
26 Mendelian randomization (MR) studies and a new two-sample MR analysis.

## 27 **Materials and Methods**

28 A literature search across major databases was conducted through May 2024 to identify MR  
29 studies linking T2DM and AD. Fixed/random-effect models provided pooled odds ratios (OR)  
30 with 95% confidence intervals (CI), and heterogeneity was assessed with the  $I^2$  statistic. For  
31 our MR analysis, we pooled genetic variants from selected studies and analyzed AD  
32 outcomes using IGAP, EADB, and UKB databases. Multiple MR methods, including inverse-  
33 variance weighted (IVW) and pleiotropy-robust approaches, were applied for validation.

## 34 **Results**

35 Of 271 articles, eight MR studies were included (sample sizes: 68,905 to 788,989), all from  
36 European ancestry. Our meta-analysis found no significant causal link between T2DM and  
37 AD (OR = 1.01, 95% CI: 0.99-1.03) with moderate heterogeneity ( $I^2 = 44.16\%$ ). Similarly,  
38 our MR analysis using 511 SNPs as instrumental variables showed no significant associations  
39 in IGAP, EADB, or UKB data, consistent across sensitivity analyses.

## 40 **Conclusions**

41 This meta-MR and MR analysis revealed no significant causal association between T2DM  
42 and AD, indicating that T2DM may not directly influence AD risk. Further research should  
43 explore other mechanisms linking these conditions.

44

45

46 **Keywords:** Type 2 diabetes, Alzheimer's disease, Mendelian randomization

## 47 **Introduction**

48 Type 2 diabetes mellitus (T2DM) is a chronic metabolic condition characterized by impaired  
49 insulin sensitivity and persistent hyperglycemia. As a significant public health challenge  
50 contributing to an increasing burden worldwide, the global diabetes prevalence in individuals  
51 aged 20-79 in 2021 was estimated to be 10.5% (536.6 million people), rising to 12.2% (783.2  
52 million) in 2045 (1). In addition to its direct health impact and the increasing healthcare costs  
53 it brings, T2DM contributes to significant morbidity and mortality through its complications,  
54 such as cardiovascular disease, neuropathy, and kidney dysfunction, posing substantial  
55 challenges to healthcare systems and public health (1-3).

56 Alzheimer's disease (AD), the most common form of dementia that contributes to 60-  
57 70% of dementia cases (4), is also a prevalent condition that significantly impacts global  
58 public health, marked by progressive cognitive decline and neurodegeneration (5).

59 Numerous epidemiological studies have reported the increased risk of dementia  
60 outcomes, especially AD, in individuals with T2DM, suggesting a potential link between  
61 these two conditions (6, 7). For instance, a meta-analysis reported a 73% higher risk of all  
62 types of dementia and a 56% increased risk of AD in individuals with T2DM (7, 8). This  
63 association has been observed consistently across diverse populations, pointing to T2DM as a  
64 significant risk factor for AD. Several biological mechanisms have been proposed to explain  
65 this relationship, including insulin resistance, chronic hyperglycemia, and inflammation (9-  
66 12).

67 Mendelian randomization (MR) analysis is a genetic epidemiology method that infers  
68 causal relationships between modifiable risk factors and health outcomes. By leveraging  
69 genetic variants as instrumental variables (IVs), MR minimizes confounding and reverse

70 causation, common limitations in observational studies (13). While MR provides a robust  
71 method for inferring causality between T2DM and various complications, there remains a  
72 lack of comprehensive synthesis regarding its impact on cognitive outcomes, particularly AD  
73 (14-16). To address this gap, our study systematically reviewed and synthesized current  
74 research on the causal relationship between T2DM and AD by aggregating data from multiple  
75 published MR studies. One major limitation of meta-MR results is the risk of overestimating  
76 effect sizes due to the repeated inclusion of the same genetic variant, which can inflate  
77 associations and bias estimates (17, 18). To minimize this risk, we pooled single nucleotide  
78 polymorphisms (SNPs) associated with T2DM from MR studies included in this review and  
79 removed duplicate variants. Using the group of non-duplicate SNPs as IVs, we conducted a  
80 two-sample MR analysis to explore the unbiased causal association between T2DM and AD.

## 81 **Materials and Methods**

### 82 **i) Systematic Review and Meta-MR**

83 To identify all relevant articles that addressed the causal associations between exposure  
84 (T2DM) and outcome (AD), we systematically searched PubMed, Web of Science and the  
85 EMBASE regardless of language from inception until May 1, 2024 (the complete search  
86 strategy can be found in S1 Appendix). The reference list of MR studies included in this  
87 review was also searched manually for other potentially relevant inclusions. The Preferred  
88 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were  
89 followed. The registered ID in PROSPERO is CRD42024609885. The review protocol is  
90 available from the request from author.

91

## 92 Search strategy

93 Two authors (SH and TL) independently implemented the search strategy. The process began  
94 with an initial screening of titles and abstracts, followed by an in-depth review of the full text  
95 for potential articles. Any disagreements between the two reviewers were addressed through  
96 discussion with a third author (FA), who provided adjudication.

## 97 Inclusion criteria

98 We included MR studies investigating the association between T2DM and AD. Eligible  
99 studies were required to report causal estimates, such as odds ratios (OR) or  $\beta$ -coefficients,  
100 presented as an absolute value per unit increase, along with the associated 95% confidence  
101 intervals (CI) or standard errors (SE). Only full original publications were considered for  
102 inclusion. In the case of duplicate cohorts, only the most recent MR studies with unique  
103 exposure-genome wide association studies (GWAS) and outcome-GWAS were retained for  
104 meta-MR.

## 105 Data Extraction

106 We extracted key details from each eligible MR study, including the first author, publication  
107 year, number of IVs, consortiums, sample size, population ancestry, MR design, analysis  
108 method, effect metrics (OR with 95% CI or  $\beta$ -coefficients with SEs), and sensitivity MR  
109 methods with their results.

## 110 Quality Assessment

111 We used the quality assessment tool incorporating ten questions designed to evaluate the  
112 quality of MR studies (19). Among the questions, three are core assumptions of MR: (1) the

113 genetic variants used as IVs must be strongly associated with the exposure of interest, (2) the  
114 genetic variants should not be associated with confounding factors, and (3) the genetic  
115 variants should influence the outcome solely through their effect on the exposure. Studies  
116 failing to address these key assumptions were excluded from the analysis.

## 117 Statistical Analysis

118 The effect estimates were combined using either a fixed-effects or random-effects model  
119 depending on the heterogeneity among the included studies. Heterogeneity between studies  
120 was quantified using the  $I^2$  statistic with values greater than 75% representing high  
121 heterogeneity (20). For studies reporting  $\beta$ -coefficients and SEs, the ORs and their  
122 corresponding CIs were obtained by exponentiating the  $\beta$ -coefficients and their respective  
123 CIs.

### 124 ii) Two-sample MR analysis:

125 We extracted information from eight eligible MR studies included in our systematic review.  
126 This included SNPs, major and reference alleles, effect allele frequency, effect size, SEs,  
127 effect metrics, p-values, closest genes, chromosomes and locations, and sample sizes. One  
128 investigator (SH) extracted the data, which was verified by the third investigator (FA).  
129 Missing data were requested from corresponding authors via e-mail.

### 130 Instrumental variables selection

131 Based on three MR assumptions, we pooled genetic variants demonstrating genome-wide  
132 significant associations ( $p < 5 \times 10^{-8}$ ) with T2DM (19, 21). These variants came from  
133 DIAbetes Genetics Replication And Meta-analysis (DIAGRAM), DIAbetes Meta-ANalysis  
134 of Trans-Ethnic association studies (DIAMANTE) consortia, and other studies (22-26). In

135 these GWASs, various definitions of T2DM used across included studies, commonly based  
136 on diagnostic criteria such as fasting glucose ( $\geq 7.0$  mmol/L), HbA1c ( $\geq 6.5\%$ ), or non-  
137 fasting glucose ( $\geq 11.1$  mmol/L), or from medical records, hospital discharge data, and  
138 electronic health registries. Details of these consortiums can be found in the **S4 Appendix**.  
139 The study design of the current MR analysis can be found in **Fig 2**.

140         Given the overlapping of SNPs across the included studies, we employed a  
141 deduplication strategy based on the p-value associated with each SNP's exposure (T2DM)  
142 and the corresponding GWAS sample size. In the final analysis, we retained only non-  
143 redundant SNPs, prioritizing those with the lowest p-values or derived from the most recent  
144 GWAS with the largest cohort size. 1,104 SNPs were initially merged from origin studies,  
145 with 859 proving to be unique. We implemented a standardisation process for the effect  
146 alleles to ensure comparability and accurate aggregation of genetic effect estimates across  
147 multiple cohorts.

148         To ensure the validity and robustness of the causal inference and to verify the  
149 assumptions underlying the MR approach, associated traits for the SNPs were manually  
150 verified using the GWAS catalog and PheWeb. These SNPs were then subjected to linkage  
151 disequilibrium (LD) clumping with a threshold of  $R^2=0.1$  and 1000 kilobases (kb). Following  
152 this clumping process, 511 SNPs remained. All SNPs demonstrated F-statistics greater than  
153 10, indicating that the genetic variants explain a significant portion of the variance in the  
154 exposure variable. The details of IVs can be found in the **S5 Appendix**. In the sensitivity  
155 analysis, a broader range of  $R^2$  (from 0.01 to 0.8) was applied to capture a more  
156 comprehensive view of the association. By systematically varying the  $R^2$  thresholds, we  
157 aimed to balance the trade-off between instrument independence and coverage, thereby  
158 assessing the consistency of the causal estimates across varying degrees of SNP correlation.



## 159 Outcome Genetic Consortia Data

160 The International Genomics of Alzheimer's Project (IGAP), European Alzheimer & Dementia  
161 Biobank (EADB) consortium and UK Biobank (UKB) from the included MR studies were  
162 utilized, which are all publicly available summary-level data (27-29). All the GWAS datasets  
163 used in this study obtained relevant ethics committee approvals, and participant informed  
164 consent at the time of their original data collection. IGAP is a comprehensive two-stage study  
165 based on GWASs of AD in individuals of European descent, which consists of Alzheimer  
166 Disease Genetics Consortium (ADGC), European Alzheimer's Disease Initiative (EADI), and  
167 other consortiums (28, 30). In the first stage, IGAP utilized genotyped and imputed data on  
168 7,055,881 SNPs to perform a meta-analysis of four previously published GWAS datasets,  
169 which included 17,008 AD cases and 37,154 controls.

170 EADB united various European cohorts and GWAS consortia, with summary  
171 estimates derived from 39,106 participants with clinically diagnosed AD, 46,828 participants  
172 with proxy AD, and 401,577 control participants without AD. Proxy AD was determined  
173 solely from the UKB through questionnaire data, where participants were asked if they had  
174 been diagnosed with AD or dementia.

175 UKB comprises 500,000 males and females from the general UK population, aged 40-  
176 69 at baseline (2006-2010). Cases were identified as algorithmically determined participants  
177 to have AD ( $N = 954$ ), while non-cases were defined as participants who were not ( $N =$   
178  $487,331$ ). The analysis employed BOLT-LLM and was adjusted for age, sex, genotyping chip,  
179 and the top 10 genetic principal components, following the procedures of the Medical  
180 Research Council-Integrative Epidemiology Unit UK Biobank GWAS pipeline. Details about  
181 UKB and the pipeline can be found elsewhere (29, 31, 32).

## 182 Statistical Methods and Sensitivity Analyses

183 We harmonized the summary SNP-T2DM and SNP-AD statistics to ensure effect size  
184 alignment and prevent strand mismatch. In this analysis, we utilized proxy SNPs where the  
185 primary SNPs were unavailable in the outcome dataset, thereby enhancing SNP coverage and  
186 retaining relevant instruments that meet the LD threshold. A minor allele frequency (MAF)  
187 threshold of 0.01 was applied to ensure that SNPs with low allele frequencies, which could  
188 introduce noise or bias, were excluded from the analysis. In MR analysis, the inverse  
189 variance weighted (IVW) method was used as the primary analysis method. The IVW method  
190 operates under the assumption that all SNPs included in the causal estimate are valid  
191 instruments, implying that they do not violate any of the fundamental assumptions of MR.

192 To assess the potential impact of pleiotropy, we evaluated heterogeneity across SNP-  
193 specific MR estimates using Cochran's Q statistic. We also performed MR-Egger regression,  
194 which provides a test for directional pleiotropy through its intercept, where a non-zero  
195 intercept suggests that pleiotropic effects are biasing the causal estimate (33, 34). We also  
196 used the weighted median estimator (WME), which allows up to 50% of the SNPs to be  
197 invalid instruments, offering a more robust causal estimate when pleiotropy is present (35,  
198 36). The simple mode and weighted mode methods further complement this by assuming that  
199 the causal effect is determined by the most frequent estimate among the SNPs, with the  
200 weighted mode giving more importance to stronger instruments (37, 38).

201 All statistical analyses were performed using the “TwoSampleMR (0.5.10)” package  
202 in R Studio (version 2024.04). All P values were two-sided, and  $P < 0.05$  was considered  
203 suggestive of statistical significance. The data, including exposures and outcomes, is all from  
204 open databases: <https://www.ebi.ac.uk/gwas/home>.

## 205 Results

### 206 i) Systematic Review and Meta-MR

207 The initial database search yielded 271 articles. Subsequent filtering to remove duplicates and  
208 articles not meeting the inclusion criteria. Further scrutiny for potential inclusions from  
209 reference lists led to 11 articles being considered for duplication cohorts' check. Among these,  
210 one was excluded because of duplicate exposure and outcome consortium (Morris 2012  
211 GWAS and IGAP); one employed the one-sample MR study design, and one didn't use IVW  
212 as the primary analysis methods. Eight MR studies met all criteria and were selected for  
213 inclusion in the meta-MR and subsequent MR analysis (15, 32, 39-44). In these eight MR  
214 studies, total sample sizes, including case and control, range from 68,905 to 788,989, all of  
215 European ancestry. All the studies passed the quality assessment. Information on individual  
216 studies included in this review (consortium, sample size, IVs, study design, population, and  
217 main results) is shown in the **S2 Appendix**. The quality assessment questions and results are  
218 shown in the **S6 and S7 Appendix**. The PRISMA diagram is shown in **Fig 1**. The PRISMA  
219 checklist can be found in **S11 Appendix**. The estimates represent the OR of AD per 1-unit  
220 higher log odds of T2DM.

221 In the meta-analysis, the Cochran's Q test yielded a value of 10.74 with p-value 0.097, the  $I^2$   
222 statistic was calculated to be 44.16%. Based on a fixed-effect model, the pooled risk estimate  
223 indicates that a genetic predisposition to T2DM was not significantly associated with an  
224 increased risk of AD (OR: 1.01; 95% CI: 0.99-1.03; p-value= 0.2) (**Fig 3**). The result of  
225 random effect model showed consistent results (**S3 Appendix**).

### 226 ii) Two-Sample MR analysis

227 IGAP dataset: The results of our MR study using the IGAP dataset, which included 440 SNPs  
228 as IVs, are presented in the **S8 Appendix** and visualized in **Fig 4a**. Although 511 SNPs were  
229 initially identified as IVs after clumping ( $R^2=0.1$ ), the final analysis included fewer SNPs  
230 due to several factors. First, not all SNPs from the clumped list had corresponding outcome  
231 data in the outcome dataset, leading to the exclusion of SNPs without matching outcome  
232 information. Additionally, despite choosing proxies where possible, some SNPs lacked  
233 suitable proxies with sufficient LD, resulting in further reduction.

234 Our findings revealed no significant causal association (OR 0.95; 95% CI: 0.86-1.05; p-value  
235 = 0.29) between genetic predisposition to T2DM and AD using the IVW method, even after  
236 applying multiple MR methods to assess the robustness of the results. The result remains  
237 insignificant in the sensitivity analysis with different clumping  $R^2$  (ranging from 0.01 to 0.8).  
238 The details of the results can be found in **Fig 5a-5e**.

239 EADB dataset: The results of this MR study, which included 490 SNPs as IVs, are presented  
240 in the **S9 Appendix** and visualized in **Fig 4b**. No significant causal association was found  
241 using the IVW method (OR 0.99; 95% CI 0.97-1.02; p-value= 0.52) also across all MR  
242 methods. The result remains insignificant in the sensitivity analysis with different clumping  
243  $R^2$  (ranging from 0.01 to 0.8). The details of the results can be found in **Fig 5a-5e**.

244 UKB dataset: The results from the UKB dataset, which included 492 SNPs as IVs, are  
245 presented in the **S10 Appendix** and visualized in **Fig 4c**, showing no significant association  
246 (OR 1.00; 95% CI 1.00-1.00; p-value = 0.96). The result remains insignificant in the  
247 sensitivity analysis with different clumping  $R^2$  (ranging from 0.01 to 0.8). The details of the  
248 results can be found in **Fig 5a-5e**.

249 No significant pleiotropy was observed in the above analyses, with the p-value of MR  
250 Egger regression above 0.05.

251

## 252 **Discussion**

253 Due to the nature of MR, which leverages genetic variants as proxies for exposures, this  
254 method can help address potential causal relationships between risk factors (T2DM) and  
255 outcomes (AD), minimizing the influence of confounding and reverse causality. Our study  
256 provides a thorough evaluation of the potential causal association between T2DM and AD by  
257 presenting findings of a meta-MR, as well as a new two-sample MR analysis based on IVs  
258 for T2DM identified from our review and outcome data from three large datasets (IGAP,  
259 EADB, UKB). In the meta-analysis of eight MR studies, we did not observe a statistically  
260 significant causal association between genetic predisposition to T2DM and AD. Similarly,  
261 our two-sample MR analyses revealed no statistically significant support for a causal  
262 association between T2DM and AD across various MR methods, such as IVW, MR-Egger,  
263 and weighted median. The results remained consistent even after employing different  
264 clumping thresholds ( $R^2$  ranging from 0.01 to 0.8), further suggesting that the genetic  
265 predisposition to T2DM does not have a strong causal impact on AD development. Notably,  
266 no evidence of directional pleiotropy, as indicated by non-significant MR-Egger intercepts  
267 across all datasets, enhancing our findings' reliability.

268 With these results, it is essential to assess the accuracy of our findings and investigate  
269 reasons for discrepancies with previous MR studies; one of the included MR studies in our  
270 review obtained significant association, which is opposite to other included studies (41).

271 Firstly, the choice of genetic variants used as IVs differs between studies. Genetic variants  
272 with varying strengths of association with T2DM could lead to inconsistent results,  
273 particularly if some studies utilize weak IVs that violate MR assumptions. Secondly,  
274 variations in data quality and population characteristics such as ancestry, age, and sex could  
275 also contribute to differing findings. Studies with more homogenous populations may yield  
276 stronger associations than those with diverse cohorts, where confounding factors might  
277 obscure true relationships. Our review showed that studies with different outcomes-GWAS  
278 may yield wider CIs (32). Thirdly, the definition of AD can affect the result of the MR  
279 analysis. Among the MR studies included in this paper, some studies used proxy AD  
280 diagnosis, which may affect the characteristics of the population (15).

281 While our study did not find strong evidence of a direct causal association,  
282 epidemiological studies frequently report links between T2DM and AD. These associations  
283 are likely driven by residual confounding factors such as age, obesity, and hypertension,  
284 which can contribute to common underlying mechanisms like metabolic dysfunction,  
285 inflammation, and vascular damage (6, 45). One possible explanation for the lack of a  
286 significant causal link could be that T2DM may influence dementia risk through pathways  
287 distinct from those involved in AD, including insulin resistance (46-48), chronic  
288 hyperglycemia (49, 50), inflammation (51-53), and vascular dysfunction (54-57). T2DM is  
289 mainly associated with vascular changes that elevate the risk for vascular dementia rather  
290 than AD. Conditions like vascular injury and small vessel disease, prevalent in individuals  
291 with T2DM, may contribute to cognitive decline and dementia through cerebrovascular  
292 damage rather than through amyloid or tau pathology, which is central to AD. Studies  
293 indicate that while the pathological changes observed in AD and vascular dementia can  
294 coexist, their mechanistic pathways may diverge, which may explain why our MR analysis  
295 did not find an increased risk of AD associated with T2DM.

296 Genetic instruments in MR studies may capture broader metabolic traits linked with  
297 T2DM, such as insulin resistance, obesity, and dyslipidemia, which could have complex  
298 effects on brain health. While these metabolic dysfunctions may increase overall dementia  
299 risk, their impact on AD pathology might be indirect or less significant. Additionally, T2DM  
300 is influenced by genetic, lifestyle, and environmental factors, and genetic variants linked to  
301 T2DM may not fully reflect the molecular mechanisms underlying AD, potentially diluting  
302 any AD-specific effect.

### 303 **Clinical Relevance**

304 The lack of a significant causal association between T2DM and AD in our study suggests that  
305 T2DM may not directly contribute to AD development. This finding challenges the common  
306 assumption that diabetes is a direct risk factor for AD and necessitates a reevaluation of the  
307 implications of T2DM for cognitive health. However, it is crucial to note that our results do  
308 not rule out the possibility that T2DM could increase dementia risk through alternative  
309 pathways.

310 Potential mechanisms, including insulin resistance, chronic hyperglycemia, vascular  
311 damage, and inflammation, may independently contribute to cognitive decline, offering an  
312 explanation for the associations observed in epidemiological studies between T2DM and  
313 dementia risk. While our findings do not support a direct link between T2DM and AD, they  
314 underscore the need for further research into the broader impact of T2DM on dementia,  
315 particularly through non-AD pathways (58-60). Future studies should focus on the  
316 differential effects of T2DM on various dementia types to better understand its role in  
317 cognitive decline, which could provide valuable insights for healthcare providers and inform  
318 strategies for prevention and intervention in at-risk populations.

## 319 **Strengths and Limitations**

320 A key strength of our study is its comprehensive methodology, which combines a systematic  
321 review and meta-analysis of existing MR studies to enhance statistical power and produce  
322 robust association estimates. Our original MR analyses conducted across multiple large-scale  
323 datasets further strengthen this. Our rigorous sensitivity analyses, utilizing various MR  
324 methods and clumping thresholds, also help mitigate potential biases such as horizontal  
325 pleiotropy. However, the limitation should be noted. First, moderate heterogeneity among  
326 MR studies was observed in our meta-MR study. We conducted additional sensitivity analysis  
327 using a random-effects model, which produced consistent results, supporting the robustness  
328 of the pooled effect estimate. Second, the generalizability of our findings may be restricted,  
329 particularly for populations outside of European ancestry, necessitating caution in applying  
330 these results broadly.

## 331 **Conclusions**

332 In conclusion, no causal association was observed in our study, which included a meta-MR  
333 and a two-sample MR analysis of T2DM and AD using large, well-powered datasets. These  
334 findings highlight the need for further research to explore other potential mechanisms linking  
335 metabolic disorders and neurodegenerative diseases, such as shared inflammatory or vascular  
336 pathways, rather than direct genetic predispositions to T2DM as a cause of AD.

337

## 338 **Acknowledgements**

## 339 **Funding**



340 S.H. is supported by the China Scholarship Council Program (No. 202208330062). The study  
341 funder was not involved in the study design, the collection, analysis, and interpretation of  
342 data, or writing of the report, and did not impose any restrictions regarding the publication of  
343 the report.

#### 344 **Competing Interests**

345 The authors have no relevant financial or non-financial interests to disclose.

#### 346 **Author Contributions**

347 F.A. conceived of the presented idea. S.H. and T.L. did the systematic review. S.H.  
348 conducted all statistical analyses under the supervision of F.A. and G.B in close collaboration  
349 with a genetic epidemiologist as a consultant. All authors discussed the results and  
350 contributed to the final manuscript.

351

352

353

354

355

356

357

358

359 **References:**

- 360 1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF  
361 Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and  
362 projections for 2045. *Diabetes Res Clin Pract.* 2022;183:109119.
- 363 2. Global, regional, and national burden of diabetes from 1990 to 2021, with projections  
364 of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.  
365 *Lancet.* 2023;402(10397):203-34.
- 366 3. Zakir M, Ahuja N, Surksha MA, Sachdev R, Kalariya Y, Nasir M, et al.  
367 Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways.  
368 *Cureus.* 2023;15(9):e45835.
- 369 4. (WHO) WHO. Dementia 2019 [Available from: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/dementia)  
370 [room/fact-sheets/detail/dementia](https://www.who.int/news-room/fact-sheets/detail/dementia). ]
- 371 5. Kumar A SJ, Lui F, et al. Alzheimer Disease. [Updated 2024 Feb 12]. In: StatPearls  
372 [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from:  
373 <https://www.ncbi.nlm.nih.gov/books/NBK499922/>.
- 374 6. Rojas M, Chávez-Castillo M, Bautista J, Ortega Á, Nava M, Salazar J, et al.  
375 Alzheimer's disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics  
376 links. *World J Diabetes.* 2021;12(6):745-66.
- 377 7. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia:  
378 A meta-analysis of prospective observational studies. *J Diabetes Investig.* 2013;4(6):640-50.
- 379 8. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in  
380 diabetes mellitus: a systematic review. *Lancet Neurol.* 2006;5(1):64-74.
- 381 9. Jayaraman A, Pike CJ. Alzheimer's disease and type 2 diabetes: multiple mechanisms  
382 contribute to interactions. *Curr Diab Rep.* 2014;14(4):476.
- 383 10. Umegaki H. Neurodegeneration in diabetes mellitus. *Adv Exp Med Biol.*  
384 2012;724:258-65.
- 385 11. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic  
386 complications. *Korean J Physiol Pharmacol.* 2014;18(1):1-14.
- 387 12. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus:  
388 mechanisms and clinical implications. *Nat Rev Endocrinol.* 2018;14(10):591-604.
- 389 13. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al.  
390 Mendelian randomization. *Nat Rev Methods Primers.* 2022;2.
- 391 14. Litkowski EM, Logue MW, Zhang R, Charest BR, Lange EM, Hokanson JE, et al.  
392 Mendelian randomization study of diabetes and dementia in the Million Veteran Program.  
393 *Alzheimer's & Dementia.* 2023;19(10):4367-76.
- 394 15. Luo J, Thomassen JQ, Bellenguez C, Grenier-Boley B, de Rojas I, Castillo A, et al.  
395 Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease. *JAMA Netw*  
396 *Open.* 2023;6(5):e2313734.
- 397 16. Hardy J, de Strooper B, Escott-Price V. Diabetes and Alzheimer's disease: shared  
398 genetic susceptibility? *Lancet Neurol.* 2022;21(11):962-4.
- 399 17. Stringer S, Wray NR, Kahn RS, Derks EM. Underestimated effect sizes in GWAS:  
400 fundamental limitations of single SNP analysis for dichotomous phenotypes. *PLoS One.*  
401 2011;6(11):e27964.
- 402 18. Uffelmann E, Huang QQ, Munung NS, de Vries J, Okada Y, Martin AR, et al.  
403 Genome-wide association studies. *Nature Reviews Methods Primers.* 2021;1(1):59.
- 404 19. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies:  
405 a guide, glossary, and checklist for clinicians. *Bmj.* 2018;362:k601.

- 406 20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-  
407 analyses. *Bmj*. 2003;327(7414):557-60.
- 408 21. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.  
409 Guidelines for performing Mendelian randomization investigations: update for summer 2023.  
410 *Wellcome Open Res*. 2019;4:186.
- 411 22. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, et al.  
412 Large-scale association analysis provides insights into the genetic architecture and  
413 pathophysiology of type 2 diabetes. *Nat Genet*. 2012;44(9):981-90.
- 414 23. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded  
415 Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes*.  
416 2017;66(11):2888-902.
- 417 24. Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al. Refining  
418 the accuracy of validated target identification through coding variant fine-mapping in type 2  
419 diabetes. *Nat Genet*. 2018;50(4):559-71.
- 420 25. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide  
421 association analyses identify 143 risk variants and putative regulatory mechanisms for type 2  
422 diabetes. *Nat Commun*. 2018;9(1):2941.
- 423 26. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al.  
424 Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4  
425 million participants in a multi-ancestry meta-analysis. *Nat Genet*. 2020;52(7):680-91.
- 426 27. Bellenguez C, Küçükali F, Jansen IE, Kleindam L, Moreno-Grau S, Amin N, et al.  
427 New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat*  
428 *Genet*. 2022;54(4):412-36.
- 429 28. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic  
430 meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ ,  
431 tau, immunity and lipid processing. *Nat Genet*. 2019;51(3):414-30.
- 432 29. Larsson SC, Woolf B, Gill D. Plasma Caffeine Levels and Risk of Alzheimer's  
433 Disease and Parkinson's Disease: Mendelian Randomization Study. *Nutrients*. 2022;14(9).
- 434 30. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al.  
435 Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's  
436 disease. *Nat Genet*. 2013;45(12):1452-8.
- 437 31. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK  
438 Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-9.
- 439 32. Garfield V, Farmaki AE, Fatemifar G, Eastwood SV, Mathur R, Rentsch CT, et al.  
440 Relationship Between Glycemia and Cognitive Function, Structural Brain Outcomes, and  
441 Dementia: A Mendelian Randomization Study in the UK Biobank. *Diabetes*.  
442 2021;70(10):2313-21.
- 443 33. Schmidt AF, Dudbridge F. Mendelian randomization with Egger pleiotropy correction  
444 and weakly informative Bayesian priors. *Int J Epidemiol*. 2018;47(4):1217-28.
- 445 34. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in  
446 Mendelian randomization studies. *Hum Mol Genet*. 2018;27(R2):R195-r208.
- 447 35. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid  
448 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*.  
449 2015;44(2):512-25.
- 450 36. Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods  
451 using summary data. *Genet Epidemiol*. 2020;44(4):313-29.
- 452 37. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian  
453 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*. 2017;46(6):1985-  
454 98.

- 455 38. Boehm FJ, Zhou X. Statistical methods for Mendelian randomization in genome-wide  
456 association studies: A review. *Comput Struct Biotechnol J*. 2022;20:2338-51.
- 457 39. Østergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, et al. Associations  
458 between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian  
459 Randomization Study. *PLoS Med*. 2015;12(6):e1001841; discussion e.
- 460 40. Andrews SJ, Fulton-Howard B, O'Reilly P, Marcora E, Goate AM. Causal  
461 Associations Between Modifiable Risk Factors and the Alzheimer's Phenome. *Ann Neurol*.  
462 2021;89(1):54-65.
- 463 41. Meng L, Wang Z, Ji HF, Shen L. Causal association evaluation of diabetes with  
464 Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's disease.  
465 *Cell Biosci*. 2022;12(1):28.
- 466 42. Pan Y, Chen W, Yan H, Wang M, Xiang X. Glycemic traits and Alzheimer's disease:  
467 a Mendelian randomization study. *Aging (Albany NY)*. 2020;12(22):22688-99.
- 468 43. Dybjer E, Kumar A, Nägga K, Engström G, Mattsson-Carlgrén N, Nilsson PM, et al.  
469 Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective  
470 cohort study. *Brain Commun*. 2023;5(2):fcad054.
- 471 44. Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of  
472 dementia: observational and Mendelian randomisation studies in 1 million individuals.  
473 *Epidemiol Psychiatr Sci*. 2020;29:e118.
- 474 45. Wang F, Guo X, Shen X, Kream RM, Mantione KJ, Stefano GB. Vascular  
475 dysfunction associated with type 2 diabetes and Alzheimer's disease: a potential etiological  
476 linkage. *Med Sci Monit Basic Res*. 2014;20:118-29.
- 477 46. Milstein JL, Ferris HA. The brain as an insulin-sensitive metabolic organ. *Mol Metab*.  
478 2021;52:101234.
- 479 47. Barone E, Di Domenico F, Perluigi M, Butterfield DA. The interplay among oxidative  
480 stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in  
481 type 2 diabetes and Alzheimer disease. *Free Radic Biol Med*. 2021;176:16-33.
- 482 48. Berlanga-Acosta J, Guillén-Nieto G, Rodríguez-Rodríguez N, Bringas-Vega ML,  
483 García-Del-Barco-Herrera D, Berlanga-Saez JO, et al. Insulin Resistance at the Crossroad of  
484 Alzheimer Disease Pathology: A Review. *Front Endocrinol (Lausanne)*. 2020;11:560375.
- 485 49. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An  
486 Integral, Updated and Critical Overview of Their Metabolic Interconnections. *Int J Mol Sci*.  
487 2023;24(11).
- 488 50. Caturano A, D'Angelo M, Mormone A, Russo V, Mollica MP, Salvatore T, et al.  
489 Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications.  
490 *Curr Issues Mol Biol*. 2023;45(8):6651-66.
- 491 51. Okdahl T, Wegeberg AM, Pociot F, Brock B, Størling J, Brock C. Low-grade  
492 inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient  
493 clinic. *BMJ Open*. 2022;12(12):e062188.
- 494 52. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G,  
495 Papaioannou S, et al. The Role of Inflammation in Diabetes: Current Concepts and Future  
496 Perspectives. *Eur Cardiol*. 2019;14(1):50-9.
- 497 53. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes,  
498 and related disorders. *Immunity*. 2022;55(1):31-55.
- 499 54. Albai O, Frandes M, Timar R, Roman D, Timar B. Risk factors for developing  
500 dementia in type 2 diabetes mellitus patients with mild cognitive impairment. *Neuropsychiatr*  
501 *Dis Treat*. 2019;15:167-75.
- 502 55. Ortiz GG, Huerta M, González-Usigli HA, Torres-Sánchez ED, Delgado-Lara DL,  
503 Pacheco-Moisés FP, et al. Cognitive disorder and dementia in type 2 diabetes mellitus. *World*  
504 *J Diabetes*. 2022;13(4):319-37.

- 505 56. Govindpani K, McNamara LG, Smith NR, Vinnakota C, Waldvogel HJ, Faull RL, et  
506 al. Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a  
507 Consequence of It? *J Clin Med*. 2019;8(5).
- 508 57. Eisenmenger LB, Peret A, Famakin BM, Spahic A, Roberts GS, Bockholt JH, et al.  
509 Vascular contributions to Alzheimer's disease. *Transl Res*. 2023;254:41-53.
- 510 58. Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, et al. Diabetic vascular diseases:  
511 molecular mechanisms and therapeutic strategies. *Signal Transduction and Targeted Therapy*.  
512 2023;8(1):152.
- 513 59. Vinuesa A, Pomilio C, Gregosa A, Bentivegna M, Presa J, Bellotto M, et al.  
514 Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for  
515 Alzheimer's Disease. *Front Neurosci*. 2021;15:653651.
- 516 60. Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid  $\beta$ -based therapy for  
517 Alzheimer's disease: challenges, successes and future. *Signal Transduction and Targeted*  
518 *Therapy*. 2023;8(1):248.

519

520

521

522

523

524

525

526

527

528

529

530

531


532

533

534

535

536




537  
538

539 **Fig 1. PRISMA ((Preferred Reporting Items for Systematic reviews and Meta-Analyses)**  
540 **flow diagram for systematic review and meta-analysis of the association between type 2**  
541 **diabetes and Alzheimer's disease.**

542 T2DM, type 2 diabetes mellitus; AD, Alzheimer's disease; MR, mendelian randomization;  
543 IVW, inverse variance weighting.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



544

545 **Fig 2. Flowchart of Mendelian Randomization analysis.**

546 T2DM, type 2 diabetes mellitus

547

548

549

550

551


552

553

554

555





556

557 **Fig 3. The pooled result of Mendelian Randomization analysis between type 2 diabetes**  
558 **mellitus and Alzheimer's disease (based on fixed effect model with heterogeneity**  
559  **$I^2=44.16\%$ )**

560 SNP, Single nucleotide polymorphism; OR, odds ratio; CI, confidence interval

561

562

563

564

565

566

567


568

569



570

**a. Type 2 diabetes mellitus and Alzheimer’s disease - MR analysis using the IGAP dataset:**




571

572

573

**b. Type 2 diabetes mellitus and Alzheimer’s disease - MR analysis using the EADB dataset:**



574


575

576

577

578

**c. Type 2 diabetes mellitus and Alzheimer's disease - MR analysis using the UKB dataset:**



580

581 **Fig 4. The causal association between type 2 diabetes mellitus and Alzheimer's disease -**  
582 **MR analysis using the IGAP dataset, EADB dataset, and UKB dataset.**

583 SNP, Single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IGAP, The  
584 International Genomics of Alzheimer's Project; EADB, European Alzheimer & Dementia  
585 Biobank consortium; UKB, UK Biobank

586

587


588

589

590

591


592 **a. Clumping  $R^2=0.01$ , based on inverse weighted variance method:**



593

594

595 **b. Clumping  $R^2=0.2$ , based on inverse weighted variance method:**



596


597

598

599

600


601 **c. Clumping R<sup>2</sup>=0.4, based on inverse weighted variance method:**



602

603

604 **d. Clumping R<sup>2</sup>=0.6, based on inverse weighted variance method:**



605

606


607

608

609

610

611 e. Clumping  $R^2=0.8$ , based on inverse weighted variance method:



612

613

614 **Fig 5. The causal association between type 2 diabetes mellitus and Alzheimer's disease**  
615 **(clumping  $R^2=0.01, 0.2, 0.4, 0.6, \text{ and } 0.8$ , based on inverse weighted variance method).**

616 SNP, Single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IGAP, The  
617 International Genomics of Alzheimer's Project; EADB, European Alzheimer & Dementia  
618 Biobank consortium

619

620